| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 12, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | $35.00 | Outperform | Oppenheimer |
| 9/12/2024 | $17.00 | Buy | Guggenheim |
| 7/22/2024 | $13.00 | Outperform | Leerink Partners |
| 6/13/2024 | $30.00 | Overweight | Piper Sandler |
| 2/17/2022 | $10.00 | Buy | HC Wainwright & Co. |
EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)
SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
S-3 - Benitec Biopharma Inc. (0001808898) (Filer)
HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. Date: November 11, 2024Time: 2:30 PMFormat: Fireside Chat & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Please contact your Guggenheim representative to schedule a 1x1 me
-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- -Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below- HAYWARD, Calif., Oct. 12, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform,
-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- -Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below- HAYWARD, Calif., Oct. 12, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform,
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00
Guggenheim initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $17.00
Leerink Partners initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $13.00
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
3 - Benitec Biopharma Inc. (0001808898) (Issuer)
3 - Benitec Biopharma Inc. (0001808898) (Issuer)
Leerink Partners analyst Mani Foroohar initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $13.
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Overweight rating and announces Price Target of $30.
Gainers CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. Omega Therapeutics (NASDAQ:OMGA) shares moved upwards b